Background The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng province, South …

Background Natural history studies have correlated serotype-specific anti–capsular
polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …

Background Vaccinating pregnant women may prevent invasive Group B Streptococcus (GBS)
disease in their young infants. In a low-middle income setting, we sought to determine an …

Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Global genomic surveillance of SARS-CoV-2 has identified variants associated with
increased transmissibility, neutralization resistance and disease severity. Here we report the …

Background The most important risk factor for early-onset (babies younger than 7 days) invasive
group B streptococcal disease is rectovaginal colonisation of the mother at delivery. We …